naa a22 4500 510764630 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1015-3 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1015-3 Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens [Elektronische Daten] [E. Habib, E. Fahmy] Purpose: The aim of this prospective, phase II clinical study is to evaluate the activity of gemcitabine and cisplatin in comparison to pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Patients and methods: The patients were recruited from May 2008 to May 2011. One group included 21 cases who received cisplatin and gemcitabine. The other group included 19 cases who received pemetrexed and carboplatin. Results: Response is superior in the pemetrexed group (p=0.041). The median follow-up was 18months (range 6-30months). Cumulative survival at 1.5years was 57.8% for the pemetrexed carboplatin group. For the gemcitabine cisplatin group, the cumulative survival proportion at 1.5years was 41% (p=0.0599). Conclusions: Pemetrexed plus carboplatin are a step forward in the treatment of mesothelioma, the prognosis for these patients remains poor. Cheaper combinations as gemcitabine and cisplatin may be considered sufficient to treat cases with advanced mesothelioma. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Mesothelioma nationallicence Chemotherapy nationallicence Gemcitabine nationallicence Pemetrexed nationallicence Habib E. Department of Clinical Oncology, Cairo University Faculty of Medicine, Cairo, Egypt aut Fahmy E. Department of Clinical Oncology, Cairo University Faculty of Medicine, Cairo, Egypt aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 965-968 1699-048X 15:11<965 2013 15 12094 https://doi.org/10.1007/s12094-013-1015-3 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1015-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Habib E. Department of Clinical Oncology, Cairo University Faculty of Medicine, Cairo, Egypt aut NATIONALLICENCE 700 1- Fahmy E. Department of Clinical Oncology, Cairo University Faculty of Medicine, Cairo, Egypt aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 965-968 1699-048X 15:11<965 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer